January AI predicts a user's glucose response to food from a short continuous glucose monitor window, then runs sensor-free using AI.
Signos is an AI-powered continuous glucose monitoring platform for weight management, cleared by the FDA as the first OTC CGM system for that use.
Including Funding rounds + valuations, Founders + executives, Products + tech stack, Headcount + HQ, Status timeline, and Roster connections.
Already subscribed? Sign in →